Affinity Investment Advisors’s Allogene Therapeutics ALLO Stock Holding History

Affinity Investment Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,209	Closed	-$376K	–	198
2021 Q4	$376K	Sell	25,209 -4,303	-15%	-$75.9K	0.15%	147
2021 Q3	$758K	Sell	29,512 -245	-0.8%	-$5.82K	0.34%	112
2021 Q2	$776K	Buy	29,757 +7,280	+32%	+$208K	0.35%	108
2021 Q1	$793K	Buy	22,477 +149	+0.7%	+$5.03K	0.29%	104
2020 Q4	$564K	Buy	22,328 +2,086	+10%	+$68K	0.23%	114
2020 Q3	$763K	Buy	+20,242	New	+$763K	0.33%	71

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Affinity Investment Advisors's ALLO Position: Q1 2022 in Review

Affinity Investment Advisors sold out of Allogene Therapeutics (ALLO) in Q1 2022, closing a stake of 25,209 shares — an estimated $376K sold.

Affinity Investment Advisors first reported a position in ALLO in Q3 2020 and held it in 6 quarters. The position peaked at $793K in Q1 2021. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

Affinity Investment Advisors reported no remaining Allogene Therapeutics position as of Q1 2022 after selling out during the quarter.
Affinity Investment Advisors sold 25,209 Allogene Therapeutics shares in Q1 2022, an estimated $376K.
Affinity Investment Advisors first reported a position in Allogene Therapeutics in Q3 2020 and held it in 6 quarters.
Affinity Investment Advisors's Allogene Therapeutics position peaked at $793K in Q1 2021.
180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Affinity Investment Advisors's 13F filing for Q1 2022, filed 5 May 2022.